Fresenius Medical Care AG (NYSE:FMS)‘s stock had its “hold” rating reissued by equities researchers at HSBC in a research report issued to clients and investors on Tuesday.
A number of other research analysts also recently commented on the company. Jefferies Group raised Fresenius Medical Care AG from an “underperform” rating to a “hold” rating in a report on Friday, July 8th. Citigroup Inc. raised Fresenius Medical Care AG from a “neutral” rating to a “buy” rating in a report on Tuesday, September 6th. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Fresenius Medical Care AG in a report on Wednesday, September 21st. Berenberg Bank reiterated a “buy” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, August 9th. Finally, SunTrust Banks Inc. set a $48.00 price target on Fresenius Medical Care AG and gave the stock a “buy” rating in a research report on Thursday, October 13th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $44.33.
Fresenius Medical Care AG (NYSE:FMS) traded up 0.60% during mid-day trading on Tuesday, hitting $42.03. The company had a trading volume of 88,289 shares. The stock’s 50 day moving average price is $43.52 and its 200 day moving average price is $43.77. Fresenius Medical Care AG has a 52-week low of $38.71 and a 52-week high of $47.52. The firm has a market cap of $25.70 billion, a P/E ratio of 23.30 and a beta of 0.58.
Fresenius Medical Care AG (NYSE:FMS) last released its earnings results on Tuesday, August 2nd. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.04. Fresenius Medical Care AG had a return on equity of 9.66% and a net margin of 6.40%. The company had revenue of $4.42 billion for the quarter, compared to the consensus estimate of $4.54 billion. On average, equities research analysts predict that Fresenius Medical Care AG will post $2.01 EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of FMS. Harding Loevner LP boosted its stake in Fresenius Medical Care AG by 40.8% in the third quarter. Harding Loevner LP now owns 3,332,640 shares of the company’s stock valued at $145,870,000 after buying an additional 966,390 shares in the last quarter. Ferguson Wellman Capital Management Inc. purchased a new position in shares of Fresenius Medical Care AG during the second quarter valued at about $5,796,000. Cambiar Investors LLC boosted its position in shares of Fresenius Medical Care AG by 5.2% in the second quarter. Cambiar Investors LLC now owns 2,333,733 shares of the company’s stock valued at $101,681,000 after buying an additional 114,840 shares during the period. Royal Bank of Canada boosted its position in shares of Fresenius Medical Care AG by 23.2% in the first quarter. Royal Bank of Canada now owns 529,505 shares of the company’s stock valued at $23,340,000 after buying an additional 99,742 shares during the period. Finally, Bank of Montreal Can purchased a new position in shares of Fresenius Medical Care AG during the second quarter valued at about $2,638,000. Hedge funds and other institutional investors own 2.49% of the company’s stock.
About Fresenius Medical Care AG
Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.
Receive News & Ratings for Fresenius Medical Care AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG and related companies with MarketBeat.com's FREE daily email newsletter.